Compare Novo Nordisk A/S (NVO) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $45.05 (market cap $198.57B), while iShares 10 20 Year Treasury Bond ETF trades at $95.88. The key difference: Novo Nordisk A/S pays a 4.03% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TLH | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $105.36 |
52-Week Low | $35.29 | $96.08 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
TLH trades at $96.52, down 0.09% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 paid in August 2026. The stock lacks disclosed financial ratios, limiting fundamental clarity amid broader market volatility driven by inflation and geopolitical tensions affecting oil prices and Treasury yields.
Outlook is cautious due to weak technicals and absent financial metrics. Risks include macroeconomic pressures from rising yields and oil prices. Investors need updated earnings reports and valuation data to assess opportunities, as current data is insufficient for a bullish view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
